IBI: Icon Bioscience wins FDA nod for long-acting cataract surgery drug

Icon Bioscience said today that the FDA has approved its application for Dexycu, a long-acting therapy designed to treat inflammation in patients who have had cataract surgery. More than four million cataract surgeries are performed each year in the U.S., according to the privately-held biopharma company, and most patients treat inflammation in their eyes using medicated [...]The post Icon Bioscience wins FDA nod for long-acting cataract surgery drug appeared first on MassDevice.